FOI 5067 – PBAC's consideration of Nurtec

This FOI request is for correspondence regarding the Public Summary Documents of the Pharmaceutical Benefits Advisory Committee (PBAC) consideration of Pfizer's Nurtec (rimegepant) since July 2023.

Downloads

FOI 5067 – PBAC's consideration of Nurtec

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

FOI number:
5067-2024
FOI release date:
Publication type:
Report
Audience:
General public
Description:

This FOI contains documents with attachments regarding the Public Summary document for Pfizer's Nurtec application considered by PBAC.

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.